Tpg Gp A, Llc - Feb 6, 2025 Form 3 Insider Report for Sionna Therapeutics, Inc. (SION)

Role
10%+ Owner
Signature
/s/ Bradford Berenson, General Counsel, TPG GP A, LLC (7)
Stock symbol
SION
Transactions as of
Feb 6, 2025
Transactions value $
$0
Form type
3
Date filed
2/6/2025, 09:36 PM
Previous filing
Dec 17, 2024
Next filing
Feb 12, 2025

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SION Series Seed Preferred Stock Feb 6, 2025 Common Stock 874K See Explanation of Responses F1, F2, F3, F4, F5, F6
holding SION Series A Preferred Stock Feb 6, 2025 Common Stock $1.24M See Explanation of Responses F1, F2, F3, F4, F5, F6
holding SION Series B Preferred Stock Feb 6, 2025 Common Stock $1.56M See Explanation of Responses F1, F2, F3, F4, F5, F6
holding SION Series C Preferred Stock Feb 6, 2025 Common Stock $1.21M See Explanation of Responses F1, F2, F3, F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each of James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Coulter and Winkelried, the "Reporting Persons"), which is the managing member of each of (i) TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., and (ii) Alabama Investments (Parallel) GP, LLC, which is the general partner of each of (a) Alabama Investments (Parallel), LP, (b) Alabama Investments (Parallel) Founder A, LP and (c) Alabama Investments (Parallel) Founder G, LP, which, collectively with TPG Group Holdings (SBS), L.P., Alabama Investments (Parallel), LP and Alabama Investments (Parallel) Founder A, LP, holds 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc.
F2 TPG Inc. is the sole member of TPG GPCo, LLC, which is the sole member of TPG Holdings II-A, LLC, which is the general partner of TPG Operating Group II, L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Operating Group I, L.P., which is the sole member of The Rise Fund GenPar Advisors, LLC, which is the general partner of The Rise Fund GenPar, L.P., which is the managing member of The Rise Fund SPV GP, LLC, which is the general partner of each of The Rise Fund Sling, L.P. and The Rise Fund Sling II, L.P. (together, the "TPG Funds").
F3 The Rise Fund Sling, L.P. directly holds (i) 684,415 shares of Common Stock ("Common Stock") of Sionna Therapeutics, Inc. (the "Issuer"), (ii) 1,276,276 shares of Series Seed Preferred Stock of the Issuer, (iii) 1,806,318 shares of Series A Preferred Stock of the Issuer and (iv) 2,275,528 shares of Series B Preferred Stock of the Issuer. The Rise Fund Sling II, L.P. directly holds 1,765,541 shares of Series C Preferred Stock (together with the Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock, "Preferred Stock") of the Issuer.
F4 Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, as amended, the shares of Preferred Stock are convertible, at the option of the holder, at any time into shares of Common Stock of the Issuer at a conversion rate (adjusted for a reverse stock split) equal to one share of Common Stock per 1.4611 share of Preferred Stock, subject to adjustment.
F5 Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any.
F6 Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

Remarks:

7. The Reporting Persons are jointly filing this Form 3 pursuant to Rule 16a-3(j) under the Exchange Act. 8. Gerald Neugebauer is signing on behalf of Messrs. Coulter and Winkelried pursuant to authorization and designation letters dated January 10, 2024, which were previously filed with the Securities and Exchange Commission.